Vistagen files new September 2026 corporate presentation; no financial or clinical data in the text

Vistagen Therapeutics, Inc.

Exhibit 99.1 is a corporate presentation dated September 2026 titled 'Harnessing the therapeutic power and potential of brain regulation with nose-to-brain neurocircuitry.'
The appended exhibit contains only the title slide; no pipeline updates, trial results, cash balance, revenue or guidance figures were disclosed.
Filing signed September 25, 2026 by President and CEO Shawn K. Singh; registrant is Vistagen Therapeutics, Inc., South San Francisco, California.
No clinical, regulatory, financing or partnership event is described, so no directional read is possible from this filing.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.